Swiss National Bank Blueprint Medicines Corp Transaction History

Swiss National Bank

  • $146 Billion
  • Q4 2024

A detailed history of Swiss National Bank transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Swiss National Bank holds 124,600 shares of BPMC stock, worth $10.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
124,600
Previous 116,200 7.23%
Holding current value
$10.5 Million
Previous $10.7 Million 1.15%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025
BUY
$82.48 - $101.39 $692,832 - $851,676
8,400 Added 7.23%
124,600 $10.9 Million
Q3 2024

Nov 07, 2024
BUY
$84.1 - $120.5 $151,380 - $216,900
1,800 Added 1.57%
116,200 $10.7 Million
Q2 2024

Aug 08, 2024
BUY
$85.18 - $108.78 $34,072 - $43,512
400 Added 0.35%
114,400 $12.3 Million
Q1 2024

May 07, 2024
BUY
$73.17 - $99.79 $36,585 - $49,895
500 Added 0.44%
114,000 $10.8 Million
Q4 2023

Feb 06, 2024
SELL
$43.96 - $92.84 $852,824 - $1.8 Million
-19,400 Reduced 14.6%
113,500 $10.5 Million
Q3 2023

Nov 08, 2023
BUY
$46.9 - $66.0 $107,870 - $151,800
2,300 Added 1.76%
132,900 $6.67 Million
Q2 2023

Aug 09, 2023
BUY
$42.2 - $66.37 $63,300 - $99,555
1,500 Added 1.16%
130,600 $8.25 Million
Q1 2023

May 10, 2023
SELL
$37.97 - $50.0 $573,347 - $755,000
-15,100 Reduced 10.47%
129,100 $5.81 Million
Q4 2022

Feb 08, 2023
BUY
$41.06 - $66.48 $119,074 - $192,792
2,900 Added 2.05%
144,200 $6.32 Million
Q3 2022

Nov 09, 2022
BUY
$49.93 - $77.7 $89,874 - $139,860
1,800 Added 1.29%
141,300 $9.31 Million
Q2 2022

Aug 09, 2022
BUY
$45.23 - $70.15 $334,702 - $519,110
7,400 Added 5.6%
139,500 $7.05 Million
Q1 2022

May 09, 2022
BUY
$54.1 - $110.08 $519,360 - $1.06 Million
9,600 Added 7.84%
132,100 $8.44 Million
Q3 2021

Nov 08, 2021
BUY
$80.98 - $109.47 $89,078 - $120,417
1,100 Added 0.91%
122,500 $12.6 Million
Q2 2021

Aug 06, 2021
BUY
$82.78 - $101.0 $33,112 - $40,400
400 Added 0.33%
121,400 $10.7 Million
Q1 2021

May 07, 2021
BUY
$90.71 - $108.28 $208,633 - $249,044
2,300 Added 1.94%
121,000 $11.8 Million
Q4 2020

Feb 05, 2021
BUY
$92.08 - $124.48 $184,160 - $248,960
2,000 Added 1.71%
118,700 $13.3 Million
Q3 2020

Nov 09, 2020
BUY
$66.45 - $92.7 $139,545 - $194,670
2,100 Added 1.83%
116,700 $10.8 Million
Q2 2020

Aug 05, 2020
BUY
$57.09 - $79.27 $1.36 Million - $1.89 Million
23,900 Added 26.35%
114,600 $8.94 Million
Q1 2020

May 08, 2020
BUY
$48.11 - $82.22 $67,354 - $115,108
1,400 Added 1.57%
90,700 $5.3 Million
Q4 2019

Feb 06, 2020
BUY
$66.73 - $82.59 $126,787 - $156,921
1,900 Added 2.17%
89,300 $7.15 Million
Q3 2019

Nov 12, 2019
BUY
$72.9 - $101.41 $685,260 - $953,254
9,400 Added 12.05%
87,400 $6.42 Million
Q2 2019

Aug 02, 2019
BUY
$73.54 - $97.8 $360,346 - $479,220
4,900 Added 6.7%
78,000 $7.36 Million
Q1 2019

May 10, 2019
BUY
$48.7 - $86.6 $160,710 - $285,780
3,300 Added 4.73%
73,100 $5.85 Million
Q4 2018

Feb 13, 2019
BUY
$45.57 - $74.26 $59,241 - $96,538
1,300 Added 1.9%
69,800 $3.76 Million
Q2 2018

Aug 09, 2018
BUY
$60.96 - $101.18 $79,248 - $131,534
1,300 Added 1.93%
68,500 $4.35 Million
Q1 2018

May 04, 2018
BUY
$73.28 - $102.95 $183,200 - $257,375
2,500 Added 3.86%
67,200 $6.16 Million
Q4 2017

Feb 07, 2018
BUY
$62.91 - $88.32 $849,285 - $1.19 Million
13,500 Added 26.37%
64,700 $4.88 Million
Q3 2017

Nov 03, 2017
BUY
$42.37 - $69.67 $2.17 Million - $3.57 Million
51,200
51,200 $3.57 Million

Others Institutions Holding BPMC

# of Institutions
383
Shares Held
61.5M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.03B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email